Comprehensive constitutional genetic and epigenetic characterization of lynch-like individuals

Autor/a

Damaso, Estela

Gonzalez Acosta, Maribel

Vargas Parra, Gardenia

Navarro, Matilde

Balmana, Judith

Ramon y Cajal, Teresa

Tuset, Noemi

Thompson, Bryony A.

Marin, Fátima

Fernández, Anna

Gómez, Carolina

Velasco, Àngela

Solanes, Ares

Iglesias, Sílvia

Urgel, Gisela

López, Consol

del Valle, Jesús

Campos, Olga

Santacana Espasa, Maria

Matias-Guiu, Xavier

Lázaro, Conxi

Valle, Laura

Brunet, Joan

Pineda, Marta

Capellà, Gabriel

Fecha de publicación

2020-12-11T14:48:40Z

2020-12-11T14:48:40Z

2020

Resumen

The causal mechanism for cancer predisposition in Lynch-like syndrome (LLS) remains unknown. Our aim was to elucidate the constitutional basis of mismatch repair (MMR) deficiency in LLS patients throughout a comprehensive (epi)genetic analysis. One hundred and fifteen LLS patients harboring MMR-deficient tumors and no germline MMR mutations were included. Mutational analysis of 26 colorectal cancer (CRC)-associated genes was performed. Pathogenicity of MMR variants was assessed by splicing and multifactorial likelihood analyses. Genome-wide methylome analysis was performed by the Infinium Human Methylation 450K Bead Chip. The multigene panel analysis revealed the presence of two MMR gene truncating mutations not previously found. Of a total of 15 additional MMR variants identified, five -present in 6 unrelated individuals- were reclassified as pathogenic. In addition, 13 predicted deleterious variants in other CRC-predisposing genes were found in 12 probands. Methylome analysis detected one constitutionalMLH1epimutation, but no additional differentially methylated regions were identified in LLS compared to LS patients or cancer-free individuals. In conclusion, the use of an ad-hoc designed gene panel combined with pathogenicity assessment of variants allowed the identification of deleterious MMR mutations as well as new LLS candidate causal genes. Constitutional epimutations in non-LS-associated genes are not responsible for LLS.


This work was funded by the Spanish Ministry of Economy and Competitiveness and cofunded by FEDER funds -a way to build Europe-(grants SAF2012-33636, SAF2015-68016-R and SAF2016-80888-R), CIBERONC, RTICC Network (RD12/0036/0031 and RD12/0036/0008), the Spanish Association Against Cancer (AECC) (080253), the Government of Catalonia (grant 2014SGR338, 2017SGR1282 and PERIS SLT002/16/0037), Fundacion Mutua Madrilena (grant AP114252013). We thank CERCA Programme for institutional support. ED was supported by a grant from the Spanish Ministry of Economy and Competitiveness. The AECC fellowship to MG-A. AF was supported by a grant from the Catalonian Health Department (SLT002/16/00409). FM was supported by CIBERONC. The Mexican National Council for Science and Technology (CONACyT) fellowship to GV.

Tipo de documento

Artículo
Versión publicada

Lengua

Inglés

Materias y palabras clave

Gens del càncer; Recte--Càncer; Mutació

Publicado por

MDPI

Documentos relacionados

Reproducció del document publicat a https://doi.org/10.3390/cancers12071799

Cancers, 2020, vol. 12, núm. 7, p.1-25

Derechos

cc-by (c) Damaso et al., 2020

http://creativecommons.org/licenses/by/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)